Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Platelet Factor 4 Attenuates Experimental Acute Liver Injury in Mice.

Drescher HK, Brandt EF, Fischer P, Dreschers S, Schwendener RA, Kowalska MA, Canbay A, Wasmuth HE, Weiskirchen R, Trautwein C, Berres ML, Kroy DC, Sahin H.

Front Physiol. 2019 Mar 26;10:326. doi: 10.3389/fphys.2019.00326. eCollection 2019.

2.

Herpes Simplex Virus Type 1 Infects Enteric Neurons and Triggers Gut Dysfunction via Macrophage Recruitment.

Brun P, Qesari M, Marconi PC, Kotsafti A, Porzionato A, Macchi V, Schwendener RA, Scarpa M, Giron MC, Palù G, Calistri A, Castagliuolo I.

Front Cell Infect Microbiol. 2018 Mar 15;8:74. doi: 10.3389/fcimb.2018.00074. eCollection 2018.

3.

Liposome Formulations of Hydrophobic Drugs.

Schwendener RA, Schott H.

Methods Mol Biol. 2017;1522:73-82.

4.

Respiratory macrophages regulate CD4 T memory responses to mucosal immunization with recombinant adenovirus-based vaccines.

Acosta-Ramirez E, Tram C, Kampen RM, Tillman MR, Schwendener RA, Xing Z, Halperin SA, Wang J.

Cell Immunol. 2016 Dec;310:53-62. doi: 10.1016/j.cellimm.2016.07.006. Epub 2016 Jul 12.

PMID:
27425590
5.

Cross-talk between tumors can affect responses to therapy.

Devaud C, John LB, Westwood JA, Yong CS, Beavis PA, Schwendener RA, Darcy PK, Kershaw MH.

Oncoimmunology. 2015 Jun 17;4(7):e975572. eCollection 2015 Jul.

6.

Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis.

Hannan TJ, Roberts PL, Riehl TE, van der Post S, Binkley JM, Schwartz DJ, Miyoshi H, Mack M, Schwendener RA, Hooton TM, Stappenbeck TS, Hansson GC, Stenson WF, Colonna M, Stapleton AE, Hultgren SJ.

EBioMedicine. 2014 Oct 24;1(1):46-57. doi: 10.1016/j.ebiom.2014.10.011. eCollection 2014 Nov.

7.

Liposomes as vaccine delivery systems: a review of the recent advances.

Schwendener RA.

Ther Adv Vaccines. 2014 Nov;2(6):159-82. doi: 10.1177/2051013614541440. Review.

8.
9.

Macrophage and T cell produced IL-10 promotes viral chronicity.

Richter K, Perriard G, Behrendt R, Schwendener RA, Sexl V, Dunn R, Kamanaka M, Flavell RA, Roers A, Oxenius A.

PLoS Pathog. 2013;9(11):e1003735. doi: 10.1371/journal.ppat.1003735. Epub 2013 Nov 7.

10.

Depletion of resident macrophages does not alter sensory regeneration in the avian cochlea.

Warchol ME, Schwendener RA, Hirose K.

PLoS One. 2012;7(12):e51574. doi: 10.1371/journal.pone.0051574. Epub 2012 Dec 11.

11.

Microparticles released by Listeria monocytogenes-infected macrophages are required for dendritic cell-elicited protective immunity.

Zhang Y, Zhang R, Zhang H, Liu J, Yang Z, Xu P, Cai W, Lu G, Cui M, Schwendener RA, Shi HZ, Xiong H, Huang B.

Cell Mol Immunol. 2012 Nov;9(6):489-96. doi: 10.1038/cmi.2012.33. Epub 2012 Oct 8.

12.

Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor necrosis factor-α-induced shock.

Linkermann A, Bräsen JH, De Zen F, Weinlich R, Schwendener RA, Green DR, Kunzendorf U, Krautwald S.

Mol Med. 2012 May 9;18:577-86. doi: 10.2119/molmed.2011.00423.

13.

A rational design for the nanoencapsulation of poisonous animal venoms in liposomes prepared with natural phospholipids.

da Costa MH, Sant'Anna OA, Quintilio W, Schwendener RA, de Araujo PS.

Curr Drug Deliv. 2012 Nov;9(6):637-44.

PMID:
22283655
14.

Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors.

Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA.

BMC Cancer. 2012 Jan 24;12:35. doi: 10.1186/1471-2407-12-35.

15.

Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice.

Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, Zeldin DC.

J Clin Invest. 2012 Jan;122(1):178-91. doi: 10.1172/JCI58128. Epub 2011 Dec 19.

16.

S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways.

Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X, Leone G, Wolf R, Yuspa SH, Ganju RK.

Cancer Res. 2012 Feb 1;72(3):604-15. doi: 10.1158/0008-5472.CAN-11-0669. Epub 2011 Dec 12.

17.

Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.

Borborema SE, Schwendener RA, Osso JA Jr, de Andrade HF Jr, do Nascimento N.

Int J Antimicrob Agents. 2011 Oct;38(4):341-7. doi: 10.1016/j.ijantimicag.2011.05.012. Epub 2011 Jul 23.

18.

N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).

Schott H, Goltz D, Schott TC, Jauch C, Schwendener RA.

Bioorg Med Chem. 2011 Jun 1;19(11):3520-6. doi: 10.1016/j.bmc.2011.04.015. Epub 2011 Apr 13.

PMID:
21536448
19.

Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.

Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, Heston W, Kim I, Kim WJ, Koh GY.

Mol Cancer. 2011 Apr 11;10:36. doi: 10.1186/1476-4598-10-36.

20.

Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy.

Zattoni M, Mura ML, Deprez F, Schwendener RA, Engelhardt B, Frei K, Fritschy JM.

J Neurosci. 2011 Mar 16;31(11):4037-50. doi: 10.1523/JNEUROSCI.6210-10.2011.

21.

Nitric oxide short-circuits interleukin-12-mediated tumor regression.

Egilmez NK, Harden JL, Virtuoso LP, Schwendener RA, Kilinc MO.

Cancer Immunol Immunother. 2011 Jun;60(6):839-45. doi: 10.1007/s00262-011-0998-2. Epub 2011 Mar 9.

22.

Liposome-based vaccines.

Schwendener RA, Ludewig B, Cerny A, Engler O.

Methods Mol Biol. 2010;605:163-75. doi: 10.1007/978-1-60327-360-2_11.

PMID:
20072880
23.

Liposome formulations of hydrophobic drugs.

Schwendener RA, Schott H.

Methods Mol Biol. 2010;605:129-38. doi: 10.1007/978-1-60327-360-2_8.

24.

Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice.

Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, Smyth MJ, Darcy PK, Kershaw MH.

Clin Cancer Res. 2009 Dec 15;15(24):7624-7633.

25.

Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.

Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Laan AC, Schott S, Losekoot N, Honeywell RJ, Peters GJ.

Invest New Drugs. 2011 Apr;29(2):248-57. doi: 10.1007/s10637-009-9353-2. Epub 2009 Dec 3.

26.

Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm.

Kim KE, Koh YJ, Jeon BH, Jang C, Han J, Kataru RP, Schwendener RA, Kim JM, Koh GY.

Am J Pathol. 2009 Oct;175(4):1733-45. doi: 10.2353/ajpath.2009.090133. Epub 2009 Sep 17.

27.

Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.

Schott H, Schott S, Schwendener RA.

Bioorg Med Chem. 2009 Oct 1;17(19):6824-31. doi: 10.1016/j.bmc.2009.08.033. Epub 2009 Aug 21.

PMID:
19744858
28.

Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated.

Torroella-Kouri M, Silvera R, Rodriguez D, Caso R, Shatry A, Opiela S, Ilkovitch D, Schwendener RA, Iragavarapu-Charyulu V, Cardentey Y, Strbo N, Lopez DM.

Cancer Res. 2009 Jun 1;69(11):4800-9. doi: 10.1158/0008-5472.CAN-08-3427. Epub 2009 May 19.

29.

Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution.

Kataru RP, Jung K, Jang C, Yang H, Schwendener RA, Baik JE, Han SH, Alitalo K, Koh GY.

Blood. 2009 May 28;113(22):5650-9. doi: 10.1182/blood-2008-09-176776. Epub 2009 Apr 3.

30.

Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.

Schott H, Hamprecht K, Schott S, Schott TC, Schwendener RA.

Bioorg Med Chem. 2009 Jan 1;17(1):303-10. doi: 10.1016/j.bmc.2008.10.081. Epub 2008 Nov 5.

31.

IL-12 p80-dependent macrophage recruitment primes the host for increased survival following a lethal respiratory viral infection.

Gunsten S, Mikols CL, Grayson MH, Schwendener RA, Agapov E, Tidwell RM, Cannon CL, Brody SL, Walter MJ.

Immunology. 2009 Apr;126(4):500-13. doi: 10.1111/j.1365-2567.2008.02923.x. Epub 2008 Sep 6.

32.

In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine.

Bijnsdorp IV, Schwendener RA, Schott H, Schott S, Fichtner I, Honeywell RJ, Losekoot N, Laan AC, Peters GJ.

Nucleic Acids Symp Ser (Oxf). 2008;(52):651. doi: 10.1093/nass/nrn329. No abstract available.

33.

A pro-inflammatory signature mediates FGF2-induced angiogenesis.

Andrés G, Leali D, Mitola S, Coltrini D, Camozzi M, Corsini M, Belleri M, Hirsch E, Schwendener RA, Christofori G, Alcamí A, Presta M.

J Cell Mol Med. 2009 Aug;13(8B):2083-108. doi: 10.1111/j.1582-4934.2008.00415.x.

34.

Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg.

Kim DD, Miwa T, Kimura Y, Schwendener RA, van Lookeren Campagne M, Song WC.

Blood. 2008 Aug 15;112(4):1109-19. doi: 10.1182/blood-2008-01-134304. Epub 2008 Jun 4.

35.

Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease.

Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, Benoit LA, Byers DE, Alevy Y, Tucker J, Swanson S, Tidwell R, Tyner JW, Morton JD, Castro M, Polineni D, Patterson GA, Schwendener RA, Allard JD, Peltz G, Holtzman MJ.

Nat Med. 2008 Jun;14(6):633-40. doi: 10.1038/nm1770. Epub 2008 May 18.

36.

Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.

Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, Alitalo K, Koh GY.

Cancer Res. 2008 Feb 15;68(4):1100-9. doi: 10.1158/0008-5472.CAN-07-2572.

37.

Liposomes in biology and medicine.

Schwendener RA.

Adv Exp Med Biol. 2007;620:117-28. Review.

38.

In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine.

Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Schott S, Laan AC, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2007;26(10-12):1619-24.

PMID:
18066839
39.

Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis.

Zehnder-Fjällman AH, Marty C, Halin C, Hohn A, Schibli R, Ballmer-Hofer K, Schwendener RA.

Oncol Rep. 2007 Oct;18(4):933-41.

PMID:
17786357
40.

Angiogenic role of LYVE-1-positive macrophages in adipose tissue.

Cho CH, Koh YJ, Han J, Sung HK, Jong Lee H, Morisada T, Schwendener RA, Brekken RA, Kang G, Oike Y, Choi TS, Suda T, Yoo OJ, Koh GY.

Circ Res. 2007 Mar 2;100(4):e47-57. Epub 2007 Feb 1.

41.

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.

Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjällman AH, Ballmer-Hofer K, Schwendener RA.

Br J Cancer. 2006 Aug 7;95(3):272-81. Epub 2006 Jul 11.

42.

Optimizing photodynamic therapy: in vivo pharmacokinetics of liposomal meta-(tetrahydroxyphenyl)chlorin in feline squamous cell carcinoma.

Buchholz J, Kaser-Hotz B, Khan T, Rohrer Bley C, Melzer K, Schwendener RA, Roos M, Walt H.

Clin Cancer Res. 2005 Oct 15;11(20):7538-44.

43.

CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection.

Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O'Sullivan MP, Walter MJ, Schwendener RA, Cook DN, Danoff TM, Holtzman MJ.

Nat Med. 2005 Nov;11(11):1180-7. Epub 2005 Oct 2.

44.

Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy.

Marty C, Langer-Machova Z, Sigrist S, Schott H, Schwendener RA, Ballmer-Hofer K.

Cancer Lett. 2006 Apr 28;235(2):298-308. Epub 2005 Jun 13.

45.

Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.

Ludwig PS, Schwendener RA, Schott H.

Eur J Med Chem. 2005 May;40(5):494-504.

PMID:
15893023
46.

Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I.

Robinson JA, Shankaramma SC, Jetter P, Kienzl U, Schwendener RA, Vrijbloed JW, Obrecht D.

Bioorg Med Chem. 2005 Mar 15;13(6):2055-64.

PMID:
15727859
47.

Targeting human cancer cells with VEGF receptor-2-directed liposomes.

Rubio Demirovic A, Marty C, Console S, Zeisberger SM, Ruch C, Jaussi R, Schwendener RA, Ballmer-Hofer K.

Oncol Rep. 2005 Feb;13(2):319-24.

PMID:
15643518
48.

Cytotoxic tumor targeting with scFv antibody-modified liposomes.

Marty C, Schwendener RA.

Methods Mol Med. 2005;109:389-402.

PMID:
15585933
49.

A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins.

Engler OB, Schwendener RA, Dai WJ, Wölk B, Pichler W, Moradpour D, Brunner T, Cerny A.

Vaccine. 2004 Nov 15;23(1):58-68.

PMID:
15519708
50.

Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes.

Marty C, Meylan C, Schott H, Ballmer-Hofer K, Schwendener RA.

Cell Mol Life Sci. 2004 Jul;61(14):1785-94.

PMID:
15241554

Supplemental Content

Loading ...
Support Center